In contrast, in this preclinical model the combination of KRAS(ON) G12C-selective and SHP2 inhibitors significantly extends survival, suggesting that patients with immune evasive tumours may obtain greater benefits from this combination. This evidence concerns the gene KRAS and neoplasm.